Livzon Pharmaceutical Group Inc. submitted its Monthly Return for Equity Issuer to Hong Kong Exchanges and Clearing Limited on 6 May 2026, covering movements in securities for the month ended 30 April 2026.

Authorised / Registered Share Capital • Ordinary H shares: 299.81 million shares at RMB 1 par value; no change during the month. • Ordinary A shares: 588.10 million shares at RMB 1 par value; no change during the month. • Total authorised share capital remained at 887.91 million shares, equivalent to RMB 887.91 million.

Issued and Treasury Shares • Issued H shares stood unchanged at 299.81 million, with zero treasury shares. • Issued A shares remained at 588.10 million, with zero treasury shares. • No share issuances, cancellations, repurchases, or treasury share movements were recorded.

Capital-Raising Instruments No share options, warrants, convertible securities, or other agreements to issue shares were outstanding or exercised during the period.

Public Float Compliance Livzon Pharma confirmed compliance with the Main Board Rule 13.32D(1) regarding the minimum 5 percent public float requirement for its H shares as at 30 April 2026.

Governance Confirmation The filing was signed by Secretary Liu Ning, affirming that all necessary authorisations, regulatory filings, and listing rule requirements related to the issuer’s securities have been satisfied.